SPOTLIGHT -
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.